Santen in the news
Ophthalmic pharmaceuticals development and sales
Tamtam found 20 recent articles about Santen.
- 参天製薬、Copilot活用で4,000超のAIエージェントを創出
Santen Pharmaceutical has rapidly integrated AI across its operations, creating over 4,000 AI agents with Microsoft Copilot, significantly boosting efficiency and developing specialized tools like "Field Coach" for medical representatives.
- Has Santen Pharmaceutical (TSE:4536) Earned Its 56% Rise And Buyback Support?
The article questions if Santen Pharmaceutical's 56.1% share price increase over three years is justified by its earnings, highlighting a new share buyback program and a potentially undervalued P/E ratio.
- Santen Pharmaceutical Co., Ltd. (SNPHY) stock price, news, quote and history
Santen Pharmaceutical Co., Ltd. researches, develops, produces, and markets ophthalmic pharmaceuticals and medical devices globally.
- 【Santen Pharmaceutical FY2027 Q2 決算説明会】参天製薬、中間期は増収増益 コア営業利益239億円で社内計画上回る 350億円自社株買いと4円増配を発表
Santen Pharmaceutical reported increased revenue and profits in H1 FY2027, exceeding internal core operating profit targets, and announced a 35 billion yen share buyback and a 4 yen dividend increase.
- Santen Pharmaceutical (TSE:4536) Stock Could Be Undervalued On Current Earnings
Santen Pharmaceutical's stock has seen significant gains, and its current valuation raises questions about whether it is justified by its earnings.
- 統合報告書「Santen Report 2026」発行 参天製薬
Santen Pharmaceutical issued its "Santen Report 2026" (fiscal year ending March 2026) in Japanese and English, detailing its mid-term business plan, initiatives in ophthalmology, and strategies for sustainable growth.
- 統合報告書「Santen Report 2026」を発行 | 参天製薬株式会社のプレスリリース
Santen released its 'Santen Report 2026' detailing its mid-term management plan, initiatives in the ophthalmology market, and strategies for sustainable growth.
- SpyGlass Acquires Advanced Vision Science from Santen
SpyGlass Pharma acquired Advanced Vision Science from Santen for $13 million to secure IOL manufacturing for its BIM-IOL System and enable future lens development.
- Santen Pharmaceutical Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:SNPHY) 2026-08-10
Santen Pharmaceutical published its Q1 2027 earnings call presentation on August 10, 2026.
- 子どもの夢を「仕方がない」で終わらせないために|Santenとセレッソ大阪が広げる、“目”の新常識
Santen partnered with Cerezo Osaka to host an event for children and parents, combining a soccer clinic with eye health education to raise awareness about the increasing prevalence and impact of childhood myopia.
- 参天製薬・子どもの近視に関する啓発メッセージの全国展開にまる子が登場!
Santen is launching a nationwide awareness campaign about childhood myopia featuring "Chibi Maruko-chan" through TV, web, and in-clinic ads starting May 11, 2026, to promote early detection and lifestyle changes.
- Santen × セレッソ大阪 楽しみながら学ぶ!目の健康&サッカー教室開催のお知らせ
Santen is co-hosting a free eye health and soccer class for elementary school students with Cerezo Osaka on May 31st.
- Santen sharpens China focus under global development strategy
Santen is increasing investment and integrating China into its global development strategy to address unmet ophthalmic needs and expand its market presence.
- Peter Sallstig, Santen Inc. USA, Santen
Peter Sallstig discusses Santen's focus on evolving eye care, emphasizing collaboration, myopia control, and the U.S. market's importance.
- AI活用に挑む大和ハウス工業、Santen、CCIグループ “Copilotアンバサダー”たちの挑戦と工夫 共創で生まれる価値を追う
Santen, Daiwa House Industry, and CCI Group implemented Microsoft 365 Copilot, using 'ambassador' programs to drive adoption and achieve significant work time reductions.
- RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%
Santen obtained approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a non-invasive treatment for acquired blepharoptosis.
- Santen Commercial Excellenceの真髄 | 企業価値向上に向けた参天製薬の挑戦
Santen discusses its "Commercial Excellence" strategy, aiming to become a leading ophthalmic company trusted globally by sharing a common "worldview" with stakeholders.
- 「サンテメディカルプラスガード&リペア」「サンテメディカルガード&リペア」11月21日(金)全国の薬局・ドラッグストアで新発売
Santen released two new eye drops, "Sante Medical Plus Guard & Repair" and "Sante Medical Guard & Repair," on November 21, 2025, to repair corneal damage and alleviate eye inflammation.
- 角膜修復&バリア機能向上成分配合「サンテメディカルガード&リペア」、「同プラスガード&リペア」新発売 参天製薬
Santen Pharmaceutical launched two new over-the-counter eye drops, "Sante Medical Guard & Repair" and "Sante Medical Plus Guard & Repair," to repair corneal damage and enhance the eye's barrier function.
- Santenと日本ハムはマイクロソフトの生成AIツール導入でどう変わった?──研究/開発での活用に脚光
Santen is extensively integrating Microsoft's generative AI tools, including Microsoft 365 Copilot and specialized AI agents, to enhance operational efficiency, accelerate research and development, and foster innovation across the company.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Santen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies